A Phase 1b/2a, Randomized, Partial Double-blind, Single Dose, Active-controlled, Dose Ranging Study to Evaluate the Safety of MEDI8852 in Adults With Acute, Uncomplicated Influenza

Trial Profile

A Phase 1b/2a, Randomized, Partial Double-blind, Single Dose, Active-controlled, Dose Ranging Study to Evaluate the Safety of MEDI8852 in Adults With Acute, Uncomplicated Influenza

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs MEDI 8852 (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 16 Dec 2016 Status changed from recruiting to completed.
    • 13 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.
    • 13 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top